abbv/agn pro-forma outlook
view report morn like last quarter
stand-alone compani top bottom line well ahead consensu
result view favor ad momentum
updat fri commentari around close consist
end time expect rais pro-forma forecast exhibit
target move repres spread
report revenu ep billion
last year well street billion
arguabl stale given pend deal nevertheless result
solid across board add momentum set
result fri link posit sourc upsid report
earn call given deal consist prior quarter magnitud
vraylar beat million versu million grew
product set import driver within
help ubrelvi ubrogepant/acut oral cgrp launch
jan overal rais ebitda billion billion
billion gener restasi entri continu push
back higher stand-alone forecast
pro-forma ebitda move billion billion
compar peer debat around
appropri valuat like pick street pro-forma forecast
like push higher next major theme go abil grow
outer year see step-down humira
biosimilar discuss call fri much step-
growth rate initi step-down potenti
strateg action bolster growth face exist leverag
expect acquisit close end european
commiss approv given jan subject approv divestitur
brazikumab inhibitor enter sale agreement
jan brazikumab azn zenpep nestl conting upon
receipt ftc/ec close abbv/agn deal point
expect deal close spread
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
cash/stock deal announc allergan came
surpris deal valu per share
share price billion allergan holder
receiv cash share thesi
allergan need pursu strateg altern
unlock trap valu announc get
holder roughli saw break-up valu expect
see deal close assum bidder come
offer driver view
stock link takeout point abbvi
offer biggest valu driver expect close earli
subject regulatory/allergan sharehold approv
see offer fair
stand-alone allergan like limit revenu growth
runway move past restasi gener
entri per abbvi incorpor modest assumpt
allergan pipelin think option
consist view gave limit credit
leverag stand-alone
allergan flat revenu compound-annual-growth-rate given
 risk competit headwind
late subject regulatory/agn sharehold
ftc updat and/or divestitur
announc ahead deal close continu focu
competit threat botox jeuveau market share
risk thesi delay deal close and/or greater
divest expect inabl convert pipelin
impact approv launch mid-may
greater-than-expect impact cgrp entri aimovig
ajovi emgal launch
bloomberg capit market estim upside/downside/target
base case scenario impli price-to-earnings
ep
assum takeout current level impli
low-single-digit spread deal price
billion share repurchas author includ
assum debt paydown sourc
capit deploy
upsid scenario impli price-to-earnings
ep
assum takeout share higher current
posit pipelin surpris high-valu program drive
assum annual oper leverag
delay gener restasi entri upsid pipelin
surpris
downsid scenario impli price-to-earnings
ep
inabl convert pipelin drive lower-than-expect
neg oper leverag within structur
greater-than-expect competit headwind core
exhibit pro-forma model
forma incom million estimate estimate estimate estimate estimate estimate commentslegaci stand-alon modellegaci stand-alon modelless net product zenpep contributiongross profit cost synergi year oper incom expens foreign exchang incom expens interest expens incom tax tax earn ep share share per rate legaci legaci net profit analysi share per exhibit
allergan incom gener us special total revenu good total gross profit oper incom reflect amort add-back per gener reportingoth incom expens incom tax provis incom net incom ep adjust dilut share dividend per ebitda analysi revenu net gross incom margin pharmaceuticals/specialti
price target reflect offer cash share current
trade price per share impli ep estim stand-alone agn
estim reflect single-digit ep growth forecast lack meaning near-term catalyst
drive upsid price target impli return support sector perform rate
risk rate price target
risk price target rate includ limit inabl convert
pipelin product competit key product prove intens model
activist pressur
allergan transform two major announc acquisit frx
close march global large-cap specialti pharmaceut compani
oper countri product sever therapeut area
medic aesthet gastroenterolog women health urolog anti-infect
analyst respons prepar research report receiv compens base upon variou factor includ
total revenu member compani capit market affili portion gener
invest bank activ member compani capit market affili
pleas note current conflict disclosur may differ public date set forth
report access current conflict disclosur client refer http //www rbccm com/gldisclosure/publicweb/
send request cm research publish bay street royal bank plaza
capit market llc make market secur allergan public limit compani
member compani capit market one affili manag co-manag public offer secur
abbvi inc past month
member compani capit market one affili receiv compens invest bank servic
abbvi inc past month
capit market llc make market secur abbvi inc
member compani capit market one affili receiv compens product servic
invest bank servic abbvi inc past month time member compani capit
market one affili provid non-secur servic abbvi inc
capit market current provid abbvi inc non-secur servic
capit market provid abbvi inc invest bank servic past month
explan capit market equiti rate system
analyst sector univers compani analyst provid research coverag accordingli rate assign
particular stock repres sole analyst view stock perform next month rel
top pick tp repres analyst best idea sector expect provid signific absolut total return month
favor risk-reward ratio
outperform expect materi outperform sector averag month
sector perform sp return expect line sector averag month
under-perform return expect materi sector averag month
restrict polici preclud certain type commun includ invest recommend
act advisor certain merger strateg transact certain circumst
rate nr rate price target estim remov due applic legal regulatori polici constraint
may includ capit market act advisori capac involv compani
specul risk rate reflect secur lower level financi oper predict illiquid share trade volum
high balanc sheet leverag limit oper histori result higher expect financi and/or stock price volatil
distribut rate
purpos rate distribut regulatori rule requir member firm assign rate one three rate categori
 buy hold/neutr sell regardless firm rate categori although capit market rate top pick/
outperform sector perform under-perform close correspond buy hold/neutr sell respect mean
rate determin rel basi
distribut rate
rate price target histori allergan public limit compani agn us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
rate price target histori abbvi inc us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
refer recommend list recommend histori chart may includ one recommend list model
portfolio maintain wealth manag one affili wealth manag recommend list includ
guid portfolio prime incom rl guid portfolio dividend growth rl guid portfolio adr rl
guid portfolio cap growth rl capit market recommend list includ strategi focu list
fundament equiti weight portfolio abbrevi rl mean date secur place
recommend list abbrevi rl mean date secur remov recommend list
equiti valuat risk
valuat method use determin risk may imped achiev price target cover compani pleas
see recent company-specif research report http //www rbcinsightresearch com send request capit
price target base equal ev/ebitda price-to-earnings estim reflect close allergan
acquisit use multipl respect reflect meaning discount histor industri averag
adjust us loss exclus humira impli return price target support sector perform rate
risk rate price target
risk rate price target includ limit tail valu risk humira still meaning contributor
combin compani acquisit risk work close integr allergan transact largest deal
histori regulatory/polit risk broadli applic sector particularli around pricing/reimburs
price target reflect offer cash share current trade price per share
impli ep estim stand-alone estim reflect single-digit ep growth forecast lack
meaning near-term catalyst drive upsid price target impli return support sector perform rate
risk rate price target
risk price target rate includ limit inabl convert pipelin product competit key
product prove intens model activist pressur
capit market polici manag conflict interest relat invest research avail us request
access current polici client refer
send request capit market research publish bay street royal bank plaza floor south
tower toronto ontario reserv right amend supplement polici time
dissemin research short-term trade idea
capit market endeavor make reason effort provid research simultan elig client
regard local time zone oversea jurisdict capit market equiti research post proprietari websit
ensur elig client receiv coverag initi chang rate target opinion time manner addit
distribut may done sale personnel via email fax electron mean regular mail client may also
receiv research via third parti vendor capit market also provid elig client access sparc firm
proprietari insight websit via email via third-parti vendor sparc contain market color commentari regard
subject compani firm current provid equiti research coverag research analyst may time time
includ short-term trade idea research report sparc short-term trade idea offer short-term view
secur may trade base market trade event result trade opportun may avail
short-term trade idea may differ price target recommend publish research report reflect
research analyst view long-term one year prospect subject compani result differ time horizon
methodolog and/or factor thu possibl subject compani common equiti consid long-term
sector perform even under-perform might present short-term buy opportun result temporari sell pressur
market convers subject compani common equiti rate long-term outperform could consid suscept
short-term downward price correct short-term trade idea rate part rate system
firm gener intend undertak oblig maintain updat short-term trade idea short-term trade
idea may suitabl investor tailor individu investor circumst object
investor make independ decis regard secur strategi discuss herein pleas contact
invest advisor institut salesperson inform regard capit market research
list recommend compani dissemin prior period pleas click
month histori sparc view http //www rbcinsightresearch com
view express report accur reflect person view respons analyst
subject secur issuer part compens respons analyst name herein directli
indirectli relat specif recommend view express respons analyst report
global industri classif standard gic develop exclus properti servic mark inc standard poor financi servic
llc licens use neither parti involv make compil gic gic classif make express impli
warranti represent respect standard classif result obtain use thereof parti herebi expressli disclaim warranti
origin accuraci complet merchant fit particular purpos respect standard classif without limit forego
event shall affili third parti involv make compil gic gic classif liabil direct indirect special
punit consequenti damag includ lost profit even notifi possibl damag
refer herein libor libo rate libor abbrevi mean london interbank offer rate administ benchmark administr
person take administr rate
capit market busi name use certain branch subsidiari royal bank canada includ dominion secur inc
capit market llc europ limit royal bank canada hong kong branch royal bank canada sydney branch inform contain
report compil capit market sourc believ reliabl represent warranti express impli made royal
canada capit market affili person accuraci complet correct opinion estim contain
report constitut capit market judgement date report subject chang without notic provid good faith without
legal respons noth report constitut legal account tax advic individu tailor invest advic materi prepar gener
circul client prepar without regard individu financi circumst object person receiv invest
servic contain report may suitabl recommend consult independ invest advisor doubt
suitabl invest servic report offer sell solicit offer buy secur past perform guid
futur perform futur return guarante loss origin capit may occur capit market research analyst compens base
part overal profit capit market includ profit attribut invest bank revenu everi provinc canada state
 countri throughout world law regul type secur invest product may offer
resid well process result secur discuss report may elig sale jurisdict capit
market may restrict publish research report time time due regulatori restrict and/ intern complianc polici case
latest publish research report avail client may reflect recent materi chang applic industri and/or applic subject compani
capit market research report current date set forth research report report circumst
constru solicit act secur broker dealer jurisdict person compani legal permit carri busi
secur broker dealer jurisdict full extent permit law neither capit market affili person accept
liabil whatsoev direct indirect consequenti loss aris connect use report inform contain herein
matter contain document may reproduc copi mean without prior written consent capit market instanc
addit inform avail request
public approv capit market llc member finra nyse sipc regist broker-deal accept
respons report dissemin unit state recipi report regist broker-deal bank act
broker dealer capac wish inform regard effect transact secur discuss report
contact place order capit market llc
public approv dominion secur inc member iiroc canadian recipi report design institut
ontario accredit investor british columbia alberta sophist purchas quebec similar permit purchas provinc
wish inform regard effect transact secur discuss report contact place order
dominion secur inc without way limit forego accept respons report dissemin canada
public approv europ limit el author prudenti regul author regul
conduct author fca prudenti regul author connect distribut unit kingdom materi gener
distribut unit kingdom retail client defin rule fca rbcel accept respons report dissemin
unit kingdom
materi distribut germani europ limit frankfurt branch regul bundesanstalt fr finanzdienstleistungsaufsicht bafin
receiv advic australia
materi distribut australia royal bank canada sydney branch abn afsl materi prepar
gener circul take account object financi situat need recipi accordingli recipi act
materi consid appropri materi regard object financi situat need materi relat acquisit
possibl acquisit particular financi product recipi australia obtain relev disclosur document prepar respect product
